NCT00500058 - A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 4, 2010

Study Completion Date

March 4, 2010

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

SB-485232

SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.

DRUG

Rituximab

Rituximab 375 mg/m\^2 will be administered by IV infusion.

Trial Locations (2)

46202

GSK Investigational Site, Indianapolis

60637

GSK Investigational Site, Chicago